SHANGHAI JUNSHI BIO YC1 Market Cap ($526.46 Million)
Market Cap & Net Worth: SHANGHAI JUNSHI BIO YC1 (8SJ)
SHANGHAI JUNSHI BIO YC1 market cap. SHANGHAI JUNSHI BIO YC1 (F:8SJ) has a market capitalization of $526.46 Million (€450.31 Million) as of November 4, 2026. Listed on the F stock exchange, this Germany-based company holds position #11632 globally and #1310 in its home market, demonstrating a -8.47% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying SHANGHAI JUNSHI BIO YC1's stock price €1.73 by its total outstanding shares 260295700 (260.30 Million). Also see cash efficiency ratio of SHANGHAI JUNSHI BIO YC1 for how efficiently the company converts equity into cash flow.
SHANGHAI JUNSHI BIO YC1 Market Cap History (2022–2026)
SHANGHAI JUNSHI BIO YC1 market cap history from 2022 to 2026. Data shows change from $1.44 Billion to $526.46 Million (-22.79% CAGR). Check SHANGHAI JUNSHI BIO YC1 (8SJ) stock price for real-time trading data and today's change.
SHANGHAI JUNSHI BIO YC1 Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how SHANGHAI JUNSHI BIO YC1's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore SHANGHAI JUNSHI BIO YC1 (8SJ) equity growth momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
0.27x
SHANGHAI JUNSHI BIO YC1's market cap is 0.27 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2022 | $1.44 Billion | $1.45 Billion | -$2.39 Billion | 0.99x | N/A |
| 2023 | $791.21 Million | $1.50 Billion | -$2.28 Billion | 0.53x | N/A |
| 2024 | $423.00 Million | $1.95 Billion | -$1.28 Billion | 0.22x | N/A |
| 2025 | $681.66 Million | $2.50 Billion | -$840.91 Million | 0.27x | N/A |
Competitor Companies of 8SJ by Market Capitalization
Companies near SHANGHAI JUNSHI BIO YC1 in the global market cap rankings as of November 4, 2026. Also see total assets of SHANGHAI JUNSHI BIO YC1 for a full breakdown of the balance sheet.
Key companies related to SHANGHAI JUNSHI BIO YC1 by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #180 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #372 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #411 globally with a market cap of $69.05 Billion USD ( AU$97.59 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #497 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #180 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $553.15 |
| #372 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $961.26 |
| #411 | CSL Ltd | AU:CSL | $69.05 Billion | AU$201.16 |
| #497 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $220.83 |
Market Capitalization of SHANGHAI JUNSHI BIO YC1 (2022–2026)
Market capitalization of SHANGHAI JUNSHI BIO YC1 from 2022 to today. Between 2022 and today, SHANGHAI JUNSHI BIO YC1's market cap moved from $1.44 Billion to $ 526.46 Million, with a yearly change of -22.79%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €526.46 Million | -22.77% |
| 2025 | €681.66 Million | +61.15% |
| 2024 | €423.00 Million | -46.54% |
| 2023 | €791.21 Million | -45.15% |
| 2022 | €1.44 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 3rd, 2026 the market cap of SHANGHAI JUNSHI BIO YC1 was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $526.46 Million USD |
| MoneyControl | $526.46 Million USD |
| MarketWatch | $526.46 Million USD |
| marketcap.company | $526.46 Million USD |
| Reuters | $526.46 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About SHANGHAI JUNSHI BIO YC1
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in China. The company's product pipelines include Tifcemalimab, an anti- B and T lymphocyte attenuator mAB which is in phase III clinical trial to treat lung cancer and lymphocyte; Roconkibart, an anti-interleukin-17A monoclonal antibody which is in pha… Read more